시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 저분자 원료의약품 시장 보고서(2025년)
Small Molecule Active Pharmaceutical Ingredient Global Market Report 2025
상품코드 : 1678368
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,496,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,390,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,284,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

저분자 의약품 원료의약품 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 8.0%로 2,852억 3,000만 달러로 성장합니다. 예측 기간 중의 성장은 정밀의료, 특수 치료, 지속가능성 노력, 원격의료의 채택, AI의 통합에 기인할 것으로 보입니다. 예측 기간의 주요 동향으로는 아웃소싱 동향, 표적 치료, 제약의 디지털화, 가상 임상시험, 고급 분석 등이 있습니다.

질병의 확산은 저분자 원료의약품(API) 시장의 성장을 가속하는 중요한 요인입니다. 질병은 환자의 신체에 영향을 미치는 특정 비정상적인 상태, 구조 또는 기능의 장애로 정의됩니다. 원료의약품(API)은 다양한 건강 상태를 치료하기 위해 바람직한 효과를 초래하는 의약품의 필수 성분입니다. 예를 들어 2023년 3월 미국 임상종양학회(ASCO)는 미국에서 연간 12,000명 이상이 신경내분비종양 진단을 받고 있으며, 2023년에는 약 171,000명이 신경내분비종양 진단을 받고 살아갈 것이라고 보고했습니다. 또한 심혈관 질환은 전 세계에서 1,790만 명의 사망을 초래하고 있습니다. 그 결과, 질병 유병률 증가는 저분자 API 시장의 주요 촉진요인으로 작용하고 있습니다.

맞춤형 의료의 채택 증가는 저분자 API 시장의 성장을 더욱 촉진할 것으로 예상됩니다. 맞춤의료(정밀의료)는 환자의 유전자, 환경, 라이프스타일의 개인차를 고려한 첨단 치료 접근법입니다. 저분자는 의약품에 배합되어 환자 고유의 유전자 프로파일과 바이오마커에 대응하도록 설계된 맞춤형 치료를 가능하게 하여 보다 효과적이고 개인화된 치료를 가능하게 합니다. 예를 들어 미국 기반의 전문 단체인 개인화된 의학 연합(Personalized Medicine Coalition)은 2022년 FDA 의약품평가연구센터(CDER)가 37개의 새로운 분자생물제제(NME)를 승인할 것이라고 보고했습니다. 이 35개의 치료용 NME 중 약 34%에 해당하는 12개의 의약품이 개인맞춤의료연합(PMC)에 의해 개인맞춤의료로 분류되었습니다. 결과적으로 맞춤의료의 채택이 저분자 API 시장의 성장을 주도하고 있는 것으로 분석됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, Covid, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

A small-molecule active pharmaceutical ingredient (API) is a substance or mixture with a low molecular weight intended for use as the active ingredient in drug or medicinal product manufacturing.

The primary types of small molecule active pharmaceutical ingredient markets are synthetic, chemical, and biological. Synthetics engage in the manufacturing of pharmaceutical drugs, with synthetic chemical APIs, also known as small molecules, constituting a significant portion of the pharmaceutical market. Various therapeutic types, including autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, dermatology, and urology, are addressed. Manufacturing methods involve in-house and contract methods, with applications spanning clinical and commercial domains.

The small molecule active pharmaceutical ingredient market research report is one of a series of new reports from The Business Research Company that provides small molecule active pharmaceutical ingredient market statistics, including small molecule active pharmaceutical ingredient industry global market size, regional shares, competitors with a small molecule active pharmaceutical ingredient market share, detailed small molecule active pharmaceutical ingredient market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule active pharmaceutical ingredient industry. This small molecule active pharmaceutical ingredient market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small molecule active pharmaceutical ingredient market size has grown strongly in recent years. It will grow from $194.18 billion in 2024 to $209.81 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to regulatory approvals, patent expirations, disease prevalence, pricing pressures, clinical trial outcomes.

The small molecule active pharmaceutical ingredient market size is expected to see strong growth in the next few years. It will grow to $285.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to precision medicine, specialty therapeutics, sustainability initiatives, telehealth adoption, integration of AI. Major trends in the forecast period include outsourcing trends, targeted therapies, digitalization in pharma, virtual clinical trials, advanced analytics.

The growing prevalence of diseases is a significant factor driving the expansion of the small molecule active pharmaceutical ingredient (API) market. A disease is defined as a specific abnormal condition, a disruption of structure or function, affecting a patient's body. Active pharmaceutical ingredients (APIs) are the essential components in pharmaceutical drugs that produce the desired effect to treat various health conditions. For example, in March 2023, the American Society of Clinical Oncology (ASCO), a U.S.-based professional organization, reported that over 12,000 individuals in the U.S. were diagnosed with neuroendocrine tumors annually, with around 171,000 people living with this diagnosis in 2023. Additionally, cardiovascular diseases have led to 17.9 million deaths worldwide. As a result, the rising prevalence of diseases continues to be a primary driver of the small molecule API market.

The increasing adoption of personalized medicine is anticipated to further drive the growth of the small molecule API market. Personalized medicine, or precision medicine, is an advanced approach to medical treatment that considers individual variations in patients' genes, environments, and lifestyles. Small molecules, when formulated into pharmaceuticals, enable the creation of tailored treatments designed to address patients' unique genetic profiles and biomarkers, leading to more effective and individualized therapies. For instance, in 2022, the Personalized Medicine Coalition, a U.S.-based professional organization, reported that the FDA's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Of these 35 therapeutic NMEs, approximately 34%-or 12 drugs-were classified as personalized medicines by the Personalized Medicine Coalition (PMC). Consequently, the adoption of personalized medicine is driving the growth of the small molecule API market.

Strategic partnerships and collaborations are a key trend in the small molecule active pharmaceutical ingredient market, with major players reinforcing their positions through such alliances. In May 2022, NovAliX, Alysophil, De Dietrich Process Systems, and Bruker collaborated to jointly develop a new approach to active pharmaceutical ingredient (API) production. The partnership aims to offer complete, standalone, and location-independent API manufacturing solutions to pharmaceutical companies and contract manufacturing organizations (CMOs).

The key players in the small molecule API market are leveraging new technologies, such as microparticle technologies, to gain a competitive edge. Evonik Industries AG, a Germany-based specialty chemical company, introduced EUDRATEC SoluFlow in March 2022. This technology significantly enhances the solubility of active pharmaceutical ingredients in oral drug products, addressing challenges related to drug solubility. EUDRATEC SoluFlow transforms poorly soluble drugs into free-flowing powders of amorphous solid dispersions, simplifying manufacturing processes and improving pharmacokinetic performance.

In November 2022, Pharmaron Beijing, a China-based life science contract research organization, acquired the API Manufacturing Facility from Recipharm for an undisclosed amount. Through this acquisition, Pharmaron aims to strengthen its integrated chemistry and manufacturing capabilities to meet the increasing demand for small molecule drug R&D and manufacturing services. Active Pharmaceutical Ingredients (API) Manufacturing is a U.S.-based company specializing in the production of small molecule active pharmaceutical ingredients.

Major companies operating in the small molecule active pharmaceutical ingredient market include Pfizer Inc., BASF SE, Roche Holding AG, F. Hoffmann-La Roche Limited, AbbVie Inc., Allergan plc, Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Glaxo Smith Kline plc, China Resources Pharmaceutical Group Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Merck KGaA, Viatris Inc., Teva Pharmaceutical Industries Limited, Johnson Matthey plc, Astellas Pharma Inc., Albemarle Corporation, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Dr Reddy's Laboratories Limited, Siegfried Holding AG, Albany Molecular Research Inc., Cipla Inc., Cambrex Corporation, Daiichi Sankyo Company Ltd., Eisai Co Ltd., Otsuka Holdings Co Ltd.

North America was the largest region in the small molecule active pharmaceutical ingredient market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the small molecule active pharmaceutical ingredient market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small molecule active pharmaceutical ingredient market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small molecule active pharmaceutical ingredient market consists of sales of standard API, HPAPI (high potency active pharmaceutical ingredients), branded synthetic API, generic synthetic API, and semi-synthetic API. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Molecule Active Pharmaceutical Ingredient Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small molecule active pharmaceutical ingredient market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for small molecule active pharmaceutical ingredient ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The small molecule active pharmaceutical ingredient market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Small Molecule Active Pharmaceutical Ingredient Market Characteristics

3. Small Molecule Active Pharmaceutical Ingredient Market Trends And Strategies

4. Small Molecule Active Pharmaceutical Ingredient Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Small Molecule Active Pharmaceutical Ingredient Growth Analysis And Strategic Analysis Framework

6. Small Molecule Active Pharmaceutical Ingredient Market Segmentation

7. Small Molecule Active Pharmaceutical Ingredient Market Regional And Country Analysis

8. Asia-Pacific Small Molecule Active Pharmaceutical Ingredient Market

9. China Small Molecule Active Pharmaceutical Ingredient Market

10. India Small Molecule Active Pharmaceutical Ingredient Market

11. Japan Small Molecule Active Pharmaceutical Ingredient Market

12. Australia Small Molecule Active Pharmaceutical Ingredient Market

13. Indonesia Small Molecule Active Pharmaceutical Ingredient Market

14. South Korea Small Molecule Active Pharmaceutical Ingredient Market

15. Western Europe Small Molecule Active Pharmaceutical Ingredient Market

16. UK Small Molecule Active Pharmaceutical Ingredient Market

17. Germany Small Molecule Active Pharmaceutical Ingredient Market

18. France Small Molecule Active Pharmaceutical Ingredient Market

19. Italy Small Molecule Active Pharmaceutical Ingredient Market

20. Spain Small Molecule Active Pharmaceutical Ingredient Market

21. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market

22. Russia Small Molecule Active Pharmaceutical Ingredient Market

23. North America Small Molecule Active Pharmaceutical Ingredient Market

24. USA Small Molecule Active Pharmaceutical Ingredient Market

25. Canada Small Molecule Active Pharmaceutical Ingredient Market

26. South America Small Molecule Active Pharmaceutical Ingredient Market

27. Brazil Small Molecule Active Pharmaceutical Ingredient Market

28. Middle East Small Molecule Active Pharmaceutical Ingredient Market

29. Africa Small Molecule Active Pharmaceutical Ingredient Market

30. Small Molecule Active Pharmaceutical Ingredient Market Competitive Landscape And Company Profiles

31. Small Molecule Active Pharmaceutical Ingredient Market Other Major And Innovative Companies

32. Global Small Molecule Active Pharmaceutical Ingredient Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Small Molecule Active Pharmaceutical Ingredient Market

34. Recent Developments In The Small Molecule Active Pharmaceutical Ingredient Market

35. Small Molecule Active Pharmaceutical Ingredient Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기